172 related articles for article (PubMed ID: 26562837)
1. Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population.
Lim S; Park SH; Park HK; Hur MH; Oh SJ; Suh YJ
PLoS One; 2015; 10(11):e0140208. PubMed ID: 26562837
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
3. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
Li Y; Zhang N; Zhang H; Yang Q
J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapy-treated triple negative breast cancer.
Bae SY; Jung SP; Lee SK; Yu J; Lee JE; Kim SW; Nam SJ
Kaohsiung J Med Sci; 2018 Dec; 34(12):663-672. PubMed ID: 30527200
[TBL] [Abstract][Full Text] [Related]
5. Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society.
Kim HS; Lee JU; Yoo TK; Chae BJ; Son D; Kim YJ; Park WC
J Breast Cancer; 2019 Dec; 22(4):599-612. PubMed ID: 31897333
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base.
Mateo AM; Pezzi TA; Sundermeyer M; Kelley CA; Klimberg VS; Pezzi CM
Ann Surg Oncol; 2017 Apr; 24(4):1050-1056. PubMed ID: 27807728
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer.
Osborne C; Challagalla JD; Eisenbeis CF; Holmes FA; Neubauer MA; Koutrelakos NW; Taboada CA; Vukelja SJ; Wilks ST; Allison MA; Reddy P; Sedlacek S; Wang Y; Asmar L; O'Shaughnessy J
Clin Breast Cancer; 2018 Feb; 18(1):e89-e95. PubMed ID: 28779904
[TBL] [Abstract][Full Text] [Related]
9. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
10. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
11. Difference in characteristics and outcomes between medullary breast carcinoma and invasive ductal carcinoma: a population based study from SEER 18 database.
Wang XX; Jiang YZ; Liu XY; Li JJ; Song CG; Shao ZM
Oncotarget; 2016 Apr; 7(16):22665-73. PubMed ID: 27009810
[TBL] [Abstract][Full Text] [Related]
12. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
13. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in small node-negative triple-negative breast cancer.
Steenbruggen TG; van Werkhoven E; van Ramshorst MS; Dezentjé VO; Kok M; Linn SC; Siesling S; Sonke GS
Eur J Cancer; 2020 Aug; 135():66-74. PubMed ID: 32554215
[TBL] [Abstract][Full Text] [Related]
15. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients.
Bae SY; Lee SK; Koo MY; Hur SM; Choi MY; Cho DH; Kim S; Choe JH; Lee JE; Kim JH; Kim JS; Nam SJ; Yang JH
Breast Cancer Res Treat; 2011 Apr; 126(2):471-8. PubMed ID: 21287362
[TBL] [Abstract][Full Text] [Related]
16. The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Lim ST; Park CH; Kim SY; Nam SJ; Kang EY; Moon BI; Lee HJ; Jeon YW; Gwak H; Suh YJ
PLoS One; 2018; 13(5):e0197523. PubMed ID: 29768496
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis.
Yang X; Tang T; Zhou T
World J Surg Oncol; 2023 Nov; 21(1):364. PubMed ID: 37996840
[TBL] [Abstract][Full Text] [Related]
19. Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
Jung M; Choi EH; Nam CM; Rha SY; Jeung HC; Lee SH; Yang WI; Roh JK; Chung HC
Ann Surg Oncol; 2013 Aug; 20(8):2615-24. PubMed ID: 23543197
[TBL] [Abstract][Full Text] [Related]
20. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
